Fundraising Fox5AM Ventures — 2020 Investments
4 investments dated 2020 · listed companies and verified rows first · show all
Vor Biopharma is a biopharmaceutical company.
BiotechCambridge, US
Nathan Jorgensen(Executive Officer)Amy Mendel(Executive Officer)Robert Ang(Executive Officer, Director)Jean-Paul Kress(President, Chief Executive Officer and Chairman of the Board)in
BoardKush Parmar(Director)inJoshua Resnick(Director)
Co-investorsOUP (Osage University Partners)RA CapitalPureTech Health
Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.
BiotechHealthtechMedfield, US
Roger Heerman(Chief Business/Operating Officer / Co-Founder)inFrazer Morgan(Chief Development Officer / Co-Founder)inRobert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)
BoardJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)
Co-investorsAtlas VentureRA CapitalEQT Life SciencesGimvSixty Degree CapitalVivo Capital+3 more
Inipharm is a clinical-stage biopharmaceutical company developing small-molecule inhibitors targeting HSD17B13 to treat severe fibrotic liver diseases, including MASH and other conditions with established genetic validation.
BiotechHealthtechMedical Devices
Brian Farmer(Co-Founder, Chief Executive Officer)inHeather Hsu, PhD(Co-Founder, Chief Scientific Officer)Michael Gallatin, PhD(Co-Founder, SAB Chair)Chuhan Chung(Chief Medical Officer)in
Co-investorsFrazier Life SciencesFrazier Healthcare PartnersWu Capital
Surrozen develops multifunctional biologic therapies that selectively activate Wnt signaling to address ophthalmic diseases with unmet medical needs.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Anna Berkenblit(Director)Harold Varmus(Director)
BoardDavid Goeddel(Director)inCraig Parker(Executive Officer, Director)Tim Kutzkey(Director)in
Co-investorsAccess BiotechnologyThe Column GroupHorizons Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.